Clinical medicine profile
Lisinopril
ACE inhibitor
- Route
- ORAL
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- Pregnancy.
- History of ACEI angioedema.
- Bilateral renal artery stenosis.
- Hyperkalaemia.
- Concomitant aliskiren in diabetes (restrictions).
Precautions
- Severe CCF, impaired renal function, lactation, aortic stenosis, NSAIDs, monitor serum lithium levels, first dose may cause hypotension especially in dehydrated cases, low sodium serum levels, diuretic treated cases, monitor renal function, may potentiate hypoglyceamic effects of insulin or oral hypoglycaemic agents, haematological monitoring.
- Avoid potassium sparing diuretics or potassium supplements.
- 11, 12, 16
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Hypertension: 2.5mg daily. Maintenance dose: 10-20mg daily (max. 40mg daily). Adjunct in heart failure treatment: 2.5mg daily. Maintenance: 5-20mg daily.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Essential monitoring; beneficial long-term in proteinuric CKD if stable creatinine/K.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Rare hepatic reactions; prodrug activation may be reduced in severe liver disease.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (ACE inhibitor).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- Hypertension, Congestive heart failure.
Adverse effects
- Persistent dry cough, voice changes, chest pain, taste disturbances, bronchospasm, blood dyscrasias, tachycardia, increased serum potassium levels, anaphylactic reactions, hepatic /renal impairment, hypotension, GI disturbances, muscle cramps, sleep disturbances, flushing, asthenia, impotence, CVS disorders.
Drug interactions
Open multi-drug checker ↗- Foundational for HFrEF, post-MI, diabetic nephropathy.
- Switch to ARB if intolerable cough without angioedema history.
Mechanism & disposition
Inhibition of the conversion of angiotensin I to angiotensin II.
Read complete mechanism
Inhibition of the conversion of angiotensin I to angiotensin II. ACE inhibitors block angiotensin-converting enzyme, reducing angiotensin II formation and increasing bradykinin. Effects: vasodilation, reduced aldosterone, favourable remodelling in HF/post-MI, reduced intraglomerular pressure.
Hours; full effect weeks
12–24 hours
ORAL
of active moieties common — adjust in CKD.
Pregnancy, lactation & diet
Contraindicated — teratogenic/fetotoxic.
Captopril/enalapril often preferred if ACEI needed in lactation — check guidance.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.